1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
TherapeuticsMD, Inc.

TherapeuticsMD, Inc.

TXMD
TherapeuticsMD, Inc.US flagNASDAQ Global Select
2.04
USD
-0.08
- -
23.61MMarket Cap

Total Valuation

TherapeuticsMD, Inc. carries a market capitalization of 23.61M, placing it among publicly traded companies globally. Its enterprise value stands at 20.79M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap23.61M
Enterprise Value20.79M

Share Statistics

TherapeuticsMD, Inc. currently has 11.57M shares outstanding.

Shares Outstanding11.57M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

TherapeuticsMD, Inc. trades at a trailing price-to-earnings ratio of 130.61. The price-to-sales ratio is 6.97, and the price-to-book ratio stands at -0.02.

PE Ratio130.61
PS Ratio6.97
PB Ratio-0.02
P/TBV Ratio1.00
P/FCF Ratio8.68
P/OCF Ratio8.66

Enterprise Valuation

EV / Sales6.20
EV / EBITDAN/A
EV / EBITN/A
EV / FCF7.69

Financial Position

TherapeuticsMD, Inc. maintains a current ratio of 3.11, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.62, indicating elevated leverage, while an interest coverage ratio of -510.40 demonstrates limited ability to service its debt obligations.

Current Ratio3.11
Quick Ratio2.50
Debt / Equity21.62
Debt / EBITDA-2.28
Interest Coverage-510.40

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)0.47
Return on Invested Capital (ROIC)-8.20
Return on Capital Employed (ROCE)-0.02
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Over the trailing twelve months, TherapeuticsMD, Inc. has paid 32,000.00 in income taxes, reflecting an effective tax rate of 27.12.

Income Tax32,000.00
Effective Tax Rate27.12

Stock Price Statistics

TherapeuticsMD, Inc.'s stock has gained approximately 88.88889% over the past 52 weeks. The 50-day moving average sits at 2.09, while the 200-day moving average is 1.77.

Beta (5Y)N/A
52-Week Price Change88.88889%
50-Day Moving Average2.09
200-Day Moving Average1.77
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, TherapeuticsMD, Inc. generated 3.35M in revenue and converted that into 179,000.00 in net income, yielding earnings per share of 0.01. EBITDA reached -2.55M, while operating income came in at -3.74M.

Revenue3.35M
Gross ProfitN/A
Operating Income-3.74M
Pretax Income118,000.00
Net Income179,000.00
EBITDA-2.55M
EBIT-3.74M
Earnings Per Share (EPS)0.01

Balance Sheet

TherapeuticsMD, Inc. holds 8.42M in cash and equivalents against 5.83M in total debt, resulting in a net debt position of -8.42M. Total book value stands at -952.28M, with working capital of 10.35M providing operational flexibility.

Cash & Cash Equivalents8.42M
Total Debt5.83M
Net Debt-8.42M
Equity (Book Value)-952.28M
Book Value Per Share-82.28
Working Capital10.35M

Cash Flow

TherapeuticsMD, Inc. produced 2.70M in operating cash flow over the past twelve months.

Operating Cash Flow2.70M
Capital ExpendituresN/A
Free Cash Flow2.70M
FCF Per Share0.23

Margins

TherapeuticsMD, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -111.66 and net profit margin of 5.34 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-111.66
Pretax Margin3.52
Profit Margin5.34
EBITDA Margin-76.11

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder YieldN/A
FCF Yield11.52

Stock Splits

TherapeuticsMD, Inc.'s most recent stock split took place on May 9, 2022 with a 50:1 split ratio.

Last Split Date5/9/2022
Split Ratio50:1

Scores

TherapeuticsMD, Inc. posts an Altman Z-Score of -37.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-37.89